Objective:Based on the findings of the KEYNOTE-048 study,pembrolizumab in combination with platinum and fluorouracil is the standard first-line treatment for recurrent or metastatic head and neck squamous cell carcino...Objective:Based on the findings of the KEYNOTE-048 study,pembrolizumab in combination with platinum and fluorouracil is the standard first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma(R/M HNSCC).The efficacy and safety of pembrolizumab combined with nab-paclitaxel and platinum in such patients remain unexplored.Methods:This single-arm phase 2 study enrolled patients with R/M HNSCC who received pembrolizumab(200 mg),nab-paclitaxel(260 mg/m^(2)),and either cisplatin(75 mg/m^(2))or carboplatin[area under the curve(AUC)5]every 21 d for up to six cycles,followed by pembrolizumab maintenance therapy.The primary endpoint was the objective response rate(ORR).Secondary endpoints included disease control rate(DCR),progression-free survival(PFS),duration of response(Do R),overall survival(OS),and safety.Exploratory multi-omics analyses were conducted.Results:Between April 23,2021,and August 20,2023,a total of 67 patients with R/M HNSCC were enrolled and received the study treatment.By the data cut-off date of March 2,2024,62(92.5%)patients had received cisplatin,while five(7.5%)patients had received carboplatin.The median follow-up duration was 12.7(range:2.3-34.8)months.The ORR was 62.7%,and the DCR was 88.1%.The median PFS,Do R,and OS were 9.7,13.0,and 18.7 months,respectively.The most common grade 3 adverse events(AEs)were leukopenia(22.4%)and neutropenia(28.4%).Genomic alterations correlated with efficacy outcomes,and dynamic changes in 17 plasma proteins were associated with treatment response.Upregulation of serum interferon(IFN)-γand interleukin(IL)8levels was linked to treatment-related AEs.Conclusions:Pembrolizumab in combination with nab-paclitaxel and platinum demonstrated promising efficacy and a manageable safety profile in patients with R/M HNSCC.Future studies are warranted to confirm these findings.展开更多
Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in Nationa...Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.Results: In the 1,085 patients, 679(62.6%) cases were nodal DLBCL(N-DLBCL) and 406 cases(37.4%) were extranodal DLBCL(EN-DLBCL). The most common sites of N-DLBCL were lymphonodus(64.8%), Waldeyer's ring(19.7%), mediastinum(12.8%) and spleen(2.7%), while in EN-DLBCL, stomach(22.4%), intestine(16.0%),nose and sinuses(8.9%), testis(8.4%), skin(7.9%), thyroid(6.9%), central nervous system(CNS)(6.4%), breast(5.7%), bone(3.4%), and salivary gland(2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival(OS) rate and progression-free survival(PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9%(P=0.008), and the 5-year PFS were57.0% and 49.0%(P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate(83.6%) and PFS rate(76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach,breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%,respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.展开更多
Objective： To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma （DLBCL）. Methods： A retrospective study of 37 patients with primary testicular DLBCL ...Objective： To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma （DLBCL）. Methods： A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed. Results： During a median follow-up period of 39.8 months （5.4-93.0 months）, the median progression-free survival （PFS） was 26.2 months （95% CI：0-65 months） and the 3-year overall survival （OS） rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage （stage Ⅰ/Ⅱ）, lactate dehydrogenase （LDH） ≤245 U/L, international prognostic index （IPI） ≤1, primary tumor diameter 〈7.5 cm, and patients who had complete response （CR） and received doxoruhicin-contained chemotherapy （P〈0.05）. There was a trend toward superior outcome for patients who received combined therapy （surgery/ chemotherapy/radiotherapy） （P=0.055）. Patients who had CR, primary tumor diameter 〈7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis. Conclusions： Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy （RT） seemed to improve survival.展开更多
Recent researches show that there are some anomalies,which are not satisfied with common sense,appearing in some special permutation flow shop scheduling problems(PFSPs).These anomalies can be divided into three diffe...Recent researches show that there are some anomalies,which are not satisfied with common sense,appearing in some special permutation flow shop scheduling problems(PFSPs).These anomalies can be divided into three different types,such as changing the processing time of some operations,changing the number of total jobs and changing the number of total machines.This paper summarizes these three types of anomalies showing in the special PFSPs and gives some examples to make them better understood.The extended critical path is proposed and the reason why these anomalies happen in special PFSPs is given:anomalies will occur in these special PFSPs when the time of the operations on the reverse critical path changes.After that,the further reason for these anomalies is presented that when any one of these three types of anomalies happens,the original constraint in the special PFSPs is destroyed,which makes the anomalies appear.Finally,the application of these anomalies in production practice is given through examples and also with the possible research directions.The main contribution of this research is analyzing the intial reason why the anomalies appear in special PFSPs and pointing out the application and the possible research directions of all these three types of anomalies.展开更多
The meta-heuristic algorithm with local search is an excellent choice for the job-shop scheduling problem(JSP).However,due to the unique nature of the JSP,local search may generate infeasible neighbourhood solutions.I...The meta-heuristic algorithm with local search is an excellent choice for the job-shop scheduling problem(JSP).However,due to the unique nature of the JSP,local search may generate infeasible neighbourhood solutions.In the existing literature,although some domain knowledge of the JSP can be used to avoid infeasible solutions,the constraint conditions in this domain knowledge are sufficient but not necessary.It may lose many feasible solutions and make the local search inadequate.By analysing the causes of infeasible neighbourhood solutions,this paper further explores the domain knowledge contained in the JSP and proposes the sufficient and necessary constraint conditions to find all feasible neighbourhood solutions,allowing the local search to be carried out thoroughly.With the proposed conditions,a new neighbourhood structure is designed in this paper.Then,a fast calculation method for all feasible neighbourhood solutions is provided,significantly reducing the calculation time compared with ordinary methods.A set of standard benchmark instances is used to evaluate the performance of the proposed neighbourhood structure and calculation method.The experimental results show that the calculation method is effective,and the new neighbourhood structure has more reliability and superiority than the other famous and influential neighbourhood structures,where 90%of the results are the best compared with three other well-known neighbourhood structures.Finally,the result from a tabu search algorithm with the new neighbourhood structure is compared with the current best results,demonstrating the superiority of the proposed neighbourhood structure.展开更多
大脑皮层的发育是脑结构形成与功能建立的重要基础,在此过程中,皮层神经元放射状迁移及胼胝体区的轴突投射是必不可少的关键环节,该环节受基因转录的调控,但相关的分子机制目前仍不明确。转录因子BMAL1(brain and muscle Arnt-likeprote...大脑皮层的发育是脑结构形成与功能建立的重要基础,在此过程中,皮层神经元放射状迁移及胼胝体区的轴突投射是必不可少的关键环节,该环节受基因转录的调控,但相关的分子机制目前仍不明确。转录因子BMAL1(brain and muscle Arnt-likeprotein1)是体内重要的生物钟节律因子之一,最新研究发现其还参与调节海马神经祖细胞增殖,提示其与神经发育存在潜在的相关性。为明确Bmal1基因在大脑皮层发育中的具体作用,本研究首先通过RT-PCR和Real-time PCR检测Bmal1基因在神经系统中的表达情况。结果表明,Bmal1基因在神经系统中表达丰富,并且在发育期的大脑内呈现特定的表达规律:在胚胎后期和出生后早期脑内表达水平相对较高,以出生后第3d为高峰。进一步通过联合使用小鼠子宫内胚胎电转和RNAi干扰方法敲减脑内神经元中Bmal1的表达水平,结果发现胚胎期皮层神经元的放射状迁移发生了延迟,延迟程度与RNAi的敲减效率呈正相关,存在一定的基因剂量?效应关系。进一步观察发现,在胚胎期脑内神经元中降低Bmal1表达水平以后,胼胝体轴突向对侧大脑半球的投射也出现了明显的缺陷。上述研究结果表明,BMAL1是大脑皮层神经元的放射状迁移以及轴突投射发育过程中的一个重要的调控分子,为从转录因子角度深入理解大脑皮层发育的分子调节机制和寻找调控靶点提供了新的线索。展开更多
Thermal error monitoring technology is the key technological support to solve the thermal error problem of heavy-duty CNC （computer numerical control） machine tools. Currently, there are many review literatures intr...Thermal error monitoring technology is the key technological support to solve the thermal error problem of heavy-duty CNC （computer numerical control） machine tools. Currently, there are many review literatures intro- ducing the thermal error research of CNC machine tools, but those mainly focus on the thermal issues in small and medium-sized CNC machine tools and seldom introduce thermal error monitoring technologies. This paper gives an overview of the research on the thermal error of CNC machine tools and emphasizes the study of thermal error of the heavy-duty CNC machine tool in three areas. These areas are the causes of thermal error of heavy-duty CNC machine tool and the issues with the temperature moni- toring technology and thermal deformation monitoring technology. A new optical measurement technology called the ＂fiber Bragg grating （FBG） distributed sensing tech- nology＂ for heavy-duty CNC machine tools is introduced in detail. This technology forms an intelligent sensing and monitoring system for heavy-duty CNC machine tools. This paper fills in the blank of this kind of review articlesto guide the development of this industry field and opens up new areas of research on the heavy-duty CNC machine tool thermal error.展开更多
Objective:Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma(PTCL).This phase 1 b study evaluated the safety,pharmacokinetics,and prelim...Objective:Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma(PTCL).This phase 1 b study evaluated the safety,pharmacokinetics,and preliminary efficacy of chidamide in combination with cyclophosphamide,doxorubicin,vincristine and prednisone(CHOP)for treatment-na?ve PTCL patients.Methods:This study was an open-label,multicenter trial composed of dose escalation and dose expansion.Patients received CHOP for six 21-d cycles and chidamide on d 1,4,8 and 11 in each cycle.Four dose levels of chidamide(20,25,30 and 35 mg)were evaluated.The primary objective was to evaluate the safety and tolerability of the combination regimen.Results:A total of 30 patients were evaluated in this study:15 in the dose-escalation part and 15 in the doseexpansion part.In the dose-escalation study,three patients were enrolled in the 35 mg chidamide cohort.One had dose-limiting toxicity with grade 3 vascular access complications,and one had grade 2 neutropenia with a sustained temperature>38°C.Dose escalation was stopped at this chidamide dose level.The most common(≥10%)grade 3 or 4 adverse events(AEs)were leukopenia(90.0%),neutropenia(83.3%),vomiting(13.3%),thrombocytopenia(10.0%)and febrile neutropenia(10.0%).No significant changes in chidamide pharmacokinetic properties were observed before and after combination treatment.The objective response rate for the 28 patients evaluable for preliminary efficacy was 89.3%(25/28),with 16(57.1%)achieving complete response or unconfirmed complete response.The estimated median progression-free survival was 14.0 months.In summary,we chose chidamide 30 mg as the recommended dose for phase 2.Conclusions:The addition of chidamide to standard CHOP chemotherapy was tolerable with promising preliminary efficacy in previously untreated PTCL patients,which supports further clinical studies with this combination regimen for the frontline treatment of PTCL.展开更多
Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone(CHOP) is an eicient treatment of non-Hodgkin's lymphoma(NHL). This study aimed to assess the eicacy and toxicity of dose-adju...Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone(CHOP) is an eicient treatment of non-Hodgkin's lymphoma(NHL). This study aimed to assess the eicacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab(R-CHOP) by examining the stem cell mobilization in NHL patients. Factors afecting the collection of CD34+ cells were also explored.Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were inancially eligible received R-CHOP for autologous peripheral blood stem cell(APBSC) mobilization; the remaining 25 patients received CHOP.Results: The median CD34+ cell yield was 7.01 × 106 cells/kg body weight(range 1.49–28.39 × 106 cells/kg body weight), with only two patients failing to meet the target CD34+ cell harvest of ber of apheresis procedures per patient was 1(range 1–3). The≥2.0 APBS× 106 cells/kg body weight. The median numC mobilization yield of the CHOP group appeared to be higher than that of the R-CHOP group(P response(CR) rate in = 0.005), whereas the success rate was similar between groups. R-CHOP elevated the completeB cell lymphoma patients as compared with CHOP(P = 0.01). No signiicant diferences in toxicity or engraftment were observed between the two groups.Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy efectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma.展开更多
基金supported by the China National Major Project for New Drug Innovation(No.2017ZX09304015)the Beijing Hope Run Special Fund of the Cancer Foundation of China(No.LC2022A30)the Beijing Vlove Charity Foundation(No.JYKY2024-0200616033)。
文摘Objective:Based on the findings of the KEYNOTE-048 study,pembrolizumab in combination with platinum and fluorouracil is the standard first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma(R/M HNSCC).The efficacy and safety of pembrolizumab combined with nab-paclitaxel and platinum in such patients remain unexplored.Methods:This single-arm phase 2 study enrolled patients with R/M HNSCC who received pembrolizumab(200 mg),nab-paclitaxel(260 mg/m^(2)),and either cisplatin(75 mg/m^(2))or carboplatin[area under the curve(AUC)5]every 21 d for up to six cycles,followed by pembrolizumab maintenance therapy.The primary endpoint was the objective response rate(ORR).Secondary endpoints included disease control rate(DCR),progression-free survival(PFS),duration of response(Do R),overall survival(OS),and safety.Exploratory multi-omics analyses were conducted.Results:Between April 23,2021,and August 20,2023,a total of 67 patients with R/M HNSCC were enrolled and received the study treatment.By the data cut-off date of March 2,2024,62(92.5%)patients had received cisplatin,while five(7.5%)patients had received carboplatin.The median follow-up duration was 12.7(range:2.3-34.8)months.The ORR was 62.7%,and the DCR was 88.1%.The median PFS,Do R,and OS were 9.7,13.0,and 18.7 months,respectively.The most common grade 3 adverse events(AEs)were leukopenia(22.4%)and neutropenia(28.4%).Genomic alterations correlated with efficacy outcomes,and dynamic changes in 17 plasma proteins were associated with treatment response.Upregulation of serum interferon(IFN)-γand interleukin(IL)8levels was linked to treatment-related AEs.Conclusions:Pembrolizumab in combination with nab-paclitaxel and platinum demonstrated promising efficacy and a manageable safety profile in patients with R/M HNSCC.Future studies are warranted to confirm these findings.
基金funded by grants from the National Science and Technology Support Program (No. 2014BAI09B12)Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (No. 2016-I2M-1-001)
文摘Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.Results: In the 1,085 patients, 679(62.6%) cases were nodal DLBCL(N-DLBCL) and 406 cases(37.4%) were extranodal DLBCL(EN-DLBCL). The most common sites of N-DLBCL were lymphonodus(64.8%), Waldeyer's ring(19.7%), mediastinum(12.8%) and spleen(2.7%), while in EN-DLBCL, stomach(22.4%), intestine(16.0%),nose and sinuses(8.9%), testis(8.4%), skin(7.9%), thyroid(6.9%), central nervous system(CNS)(6.4%), breast(5.7%), bone(3.4%), and salivary gland(2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival(OS) rate and progression-free survival(PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9%(P=0.008), and the 5-year PFS were57.0% and 49.0%(P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate(83.6%) and PFS rate(76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach,breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%,respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.
文摘Objective： To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma （DLBCL）. Methods： A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed. Results： During a median follow-up period of 39.8 months （5.4-93.0 months）, the median progression-free survival （PFS） was 26.2 months （95% CI：0-65 months） and the 3-year overall survival （OS） rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage （stage Ⅰ/Ⅱ）, lactate dehydrogenase （LDH） ≤245 U/L, international prognostic index （IPI） ≤1, primary tumor diameter 〈7.5 cm, and patients who had complete response （CR） and received doxoruhicin-contained chemotherapy （P〈0.05）. There was a trend toward superior outcome for patients who received combined therapy （surgery/ chemotherapy/radiotherapy） （P=0.055）. Patients who had CR, primary tumor diameter 〈7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis. Conclusions： Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy （RT） seemed to improve survival.
基金Supported by National Natural Science Foundation of China(Grant No.51825502).
文摘Recent researches show that there are some anomalies,which are not satisfied with common sense,appearing in some special permutation flow shop scheduling problems(PFSPs).These anomalies can be divided into three different types,such as changing the processing time of some operations,changing the number of total jobs and changing the number of total machines.This paper summarizes these three types of anomalies showing in the special PFSPs and gives some examples to make them better understood.The extended critical path is proposed and the reason why these anomalies happen in special PFSPs is given:anomalies will occur in these special PFSPs when the time of the operations on the reverse critical path changes.After that,the further reason for these anomalies is presented that when any one of these three types of anomalies happens,the original constraint in the special PFSPs is destroyed,which makes the anomalies appear.Finally,the application of these anomalies in production practice is given through examples and also with the possible research directions.The main contribution of this research is analyzing the intial reason why the anomalies appear in special PFSPs and pointing out the application and the possible research directions of all these three types of anomalies.
基金Supported by National Natural Science Foundation of China(Grant Nos.U21B2029 and 51825502).
文摘The meta-heuristic algorithm with local search is an excellent choice for the job-shop scheduling problem(JSP).However,due to the unique nature of the JSP,local search may generate infeasible neighbourhood solutions.In the existing literature,although some domain knowledge of the JSP can be used to avoid infeasible solutions,the constraint conditions in this domain knowledge are sufficient but not necessary.It may lose many feasible solutions and make the local search inadequate.By analysing the causes of infeasible neighbourhood solutions,this paper further explores the domain knowledge contained in the JSP and proposes the sufficient and necessary constraint conditions to find all feasible neighbourhood solutions,allowing the local search to be carried out thoroughly.With the proposed conditions,a new neighbourhood structure is designed in this paper.Then,a fast calculation method for all feasible neighbourhood solutions is provided,significantly reducing the calculation time compared with ordinary methods.A set of standard benchmark instances is used to evaluate the performance of the proposed neighbourhood structure and calculation method.The experimental results show that the calculation method is effective,and the new neighbourhood structure has more reliability and superiority than the other famous and influential neighbourhood structures,where 90%of the results are the best compared with three other well-known neighbourhood structures.Finally,the result from a tabu search algorithm with the new neighbourhood structure is compared with the current best results,demonstrating the superiority of the proposed neighbourhood structure.
文摘大脑皮层的发育是脑结构形成与功能建立的重要基础,在此过程中,皮层神经元放射状迁移及胼胝体区的轴突投射是必不可少的关键环节,该环节受基因转录的调控,但相关的分子机制目前仍不明确。转录因子BMAL1(brain and muscle Arnt-likeprotein1)是体内重要的生物钟节律因子之一,最新研究发现其还参与调节海马神经祖细胞增殖,提示其与神经发育存在潜在的相关性。为明确Bmal1基因在大脑皮层发育中的具体作用,本研究首先通过RT-PCR和Real-time PCR检测Bmal1基因在神经系统中的表达情况。结果表明,Bmal1基因在神经系统中表达丰富,并且在发育期的大脑内呈现特定的表达规律:在胚胎后期和出生后早期脑内表达水平相对较高,以出生后第3d为高峰。进一步通过联合使用小鼠子宫内胚胎电转和RNAi干扰方法敲减脑内神经元中Bmal1的表达水平,结果发现胚胎期皮层神经元的放射状迁移发生了延迟,延迟程度与RNAi的敲减效率呈正相关,存在一定的基因剂量?效应关系。进一步观察发现,在胚胎期脑内神经元中降低Bmal1表达水平以后,胼胝体轴突向对侧大脑半球的投射也出现了明显的缺陷。上述研究结果表明,BMAL1是大脑皮层神经元的放射状迁移以及轴突投射发育过程中的一个重要的调控分子,为从转录因子角度深入理解大脑皮层发育的分子调节机制和寻找调控靶点提供了新的线索。
基金Supported by National Natural Science Foundation of China(Grant No.51475343)International Science and Technology Cooperation Program of China(Grant No.2015DFA70340)
文摘Thermal error monitoring technology is the key technological support to solve the thermal error problem of heavy-duty CNC （computer numerical control） machine tools. Currently, there are many review literatures intro- ducing the thermal error research of CNC machine tools, but those mainly focus on the thermal issues in small and medium-sized CNC machine tools and seldom introduce thermal error monitoring technologies. This paper gives an overview of the research on the thermal error of CNC machine tools and emphasizes the study of thermal error of the heavy-duty CNC machine tool in three areas. These areas are the causes of thermal error of heavy-duty CNC machine tool and the issues with the temperature moni- toring technology and thermal deformation monitoring technology. A new optical measurement technology called the ＂fiber Bragg grating （FBG） distributed sensing tech- nology＂ for heavy-duty CNC machine tools is introduced in detail. This technology forms an intelligent sensing and monitoring system for heavy-duty CNC machine tools. This paper fills in the blank of this kind of review articlesto guide the development of this industry field and opens up new areas of research on the heavy-duty CNC machine tool thermal error.
基金supported by the sponsor Shenzhen Chipscreen Biosciences Co.,LTD.by grants from the China National Major Project for New Drug Innovation(No.2017ZX09304015)the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)(No.2016-I2M-1-001)。
文摘Objective:Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma(PTCL).This phase 1 b study evaluated the safety,pharmacokinetics,and preliminary efficacy of chidamide in combination with cyclophosphamide,doxorubicin,vincristine and prednisone(CHOP)for treatment-na?ve PTCL patients.Methods:This study was an open-label,multicenter trial composed of dose escalation and dose expansion.Patients received CHOP for six 21-d cycles and chidamide on d 1,4,8 and 11 in each cycle.Four dose levels of chidamide(20,25,30 and 35 mg)were evaluated.The primary objective was to evaluate the safety and tolerability of the combination regimen.Results:A total of 30 patients were evaluated in this study:15 in the dose-escalation part and 15 in the doseexpansion part.In the dose-escalation study,three patients were enrolled in the 35 mg chidamide cohort.One had dose-limiting toxicity with grade 3 vascular access complications,and one had grade 2 neutropenia with a sustained temperature>38°C.Dose escalation was stopped at this chidamide dose level.The most common(≥10%)grade 3 or 4 adverse events(AEs)were leukopenia(90.0%),neutropenia(83.3%),vomiting(13.3%),thrombocytopenia(10.0%)and febrile neutropenia(10.0%).No significant changes in chidamide pharmacokinetic properties were observed before and after combination treatment.The objective response rate for the 28 patients evaluable for preliminary efficacy was 89.3%(25/28),with 16(57.1%)achieving complete response or unconfirmed complete response.The estimated median progression-free survival was 14.0 months.In summary,we chose chidamide 30 mg as the recommended dose for phase 2.Conclusions:The addition of chidamide to standard CHOP chemotherapy was tolerable with promising preliminary efficacy in previously untreated PTCL patients,which supports further clinical studies with this combination regimen for the frontline treatment of PTCL.
基金supported in part by Grants from National Science-Technology Support Plan Projects of China (2014BAI09B12)National Major Project for New Drug Innovation of China (2008ZX09312 and 2012ZX09303012)the Ministry of Education Doctor Foundation of China (20010023018, 20050023045, and 200800230019)
文摘Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone(CHOP) is an eicient treatment of non-Hodgkin's lymphoma(NHL). This study aimed to assess the eicacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab(R-CHOP) by examining the stem cell mobilization in NHL patients. Factors afecting the collection of CD34+ cells were also explored.Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were inancially eligible received R-CHOP for autologous peripheral blood stem cell(APBSC) mobilization; the remaining 25 patients received CHOP.Results: The median CD34+ cell yield was 7.01 × 106 cells/kg body weight(range 1.49–28.39 × 106 cells/kg body weight), with only two patients failing to meet the target CD34+ cell harvest of ber of apheresis procedures per patient was 1(range 1–3). The≥2.0 APBS× 106 cells/kg body weight. The median numC mobilization yield of the CHOP group appeared to be higher than that of the R-CHOP group(P response(CR) rate in = 0.005), whereas the success rate was similar between groups. R-CHOP elevated the completeB cell lymphoma patients as compared with CHOP(P = 0.01). No signiicant diferences in toxicity or engraftment were observed between the two groups.Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy efectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma.
